The University of Texas MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2026

The University of Texas MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2026

The University of Texas MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2026 is an intensive six-day board review designed for physicians preparing for American Board of Internal Medicine (ABIM) certification or recertification examinations in Hematology and Medical Oncology.

The program provides a comprehensive review of current standards of care in malignant and non-malignant hematology, solid tumor oncology, clinical pharmacology, molecular genetics, cancer risk assessment, supportive care, and contemporary cancer treatment.

+ Target Audience

This program is designed for healthcare professionals involved in the diagnosis, treatment, and multidisciplinary management of patients with cancer, blood disorders, and hematologic malignancies.

It is particularly relevant for:

• Medical Oncologists
• Hematologists
• Hematology-Oncology Fellows
• Thoracic Surgeons
• Otolaryngologists / Head and Neck Surgeons
• Endocrinologists
• Neuro-Oncologists
• Neurological Surgeons
• Gynecologic Oncologists
• Palliative Care Physicians
• Medical Geneticists
• Breast Surgical Oncologists
• Urologists
• Dermatologists
• Gastroenterologists
• Infectious Disease Specialists
• Transfusion Medicine Specialists
• Hematopathologists
• Oncology Pharmacists
• Advanced Practice Providers
• Residents and Fellows
• Students and Trainees

+ Information

The course is a 6-day comprehensive review of current standards and practices in the management of patients with blood disorders and malignancy.

It is designed to enable participants to effectively prepare for the American Board of Internal Medicine certification and recertification examinations in Hematology and Medical Oncology.

The curriculum incorporates important advances in:

• Clinical pharmacology
• Molecular genetics
• Cancer risk assessment
• Hematologic malignancies
• Solid tumor oncology
• Classical hematology
• Radiation oncology
• Targeted cancer therapies
• Cellular and immune-based therapies
• Supportive care
• Contemporary standards of cancer treatment

The 2026 course is presented by The University of Texas MD Anderson Cancer Center as a live virtual educational program.

Course Details

• Course: A Comprehensive Board Review in Hematology and Medical Oncology
• Institution: The University of Texas MD Anderson Cancer Center
• Year: 2026
• Dates: September 14–19, 2026
• Duration: 6 Days
• Format: Virtual Live Streaming Course
• Main Focus: Hematology and Medical Oncology Board Review
• Board Preparation: ABIM Hematology and Medical Oncology Certification / Recertification

CME / MOC Credits

• AMA PRA Category 1 Credits™: 51.25 hours
• ABIM MOC Part 2: 51.25 hours
• Non-Physician Attendance: 51.25 hours

The official MD Anderson course listing confirms the dates, virtual format, and 51.25 credit hours.

Program Overview

The MD Anderson Comprehensive Board Review provides an extensive review of hematology and medical oncology, combining board-focused education with clinically relevant updates in contemporary cancer medicine.

The curriculum spans major areas of:

• Solid tumor oncology
• Malignant hematology
• Classical / non-malignant hematology
• Hematopoietic stem cell transplantation
• Cellular and immune-based therapies
• Molecular oncology
• Cancer genetics
• Targeted treatments
• Supportive oncology
• Infectious complications in cancer patients
• Pharmacologic management of malignancies

The program is structured to help learners consolidate high-yield knowledge for board examinations while remaining current with evolving standards of cancer and hematologic care.

Learning Objectives

At the conclusion of this activity, learners will be able to:

• Apply knowledge gained to prepare for the hematology and medical oncology subspecialty and recertification examinations in hematology and medical oncology.
• Utilize current standards of care for patients with cancer, blood disorders and malignancies.
• Demonstrate proficiency of knowledge in hematology and medical oncology.
• Incorporate recent advances in management of hematologic and oncologic patients.

These objectives match the official 2026 MD Anderson course objectives.

Official Program Topics

The 2026 curriculum includes a broad range of oncology and hematology topics designed for both board examination preparation and clinical practice.

Solid Tumor Oncology

• Breast Cancer
• Lung Cancer
• Gastrointestinal Malignancies
• Colorectal Cancer
• Anal Cancer
• Genitourinary Oncology
• Gynecologic Malignancies
• Melanoma
• Head and Neck Cancer
• Endocrine Malignancies
• Central Nervous System Tumors
• Sarcomas
• Cancer Biology
• Systemic Therapy
• Adjuvant Therapy
• Metastatic Disease Management

The official 2026 schedule includes dedicated solid-tumor sessions such as colorectal cancer biology and adjuvant therapy, metastatic colorectal and anal cancer, genitourinary oncology, gastrointestinal oncology, and melanoma.

Malignant Hematology

• Acute Myeloid Leukemia
• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia
• Chronic Lymphocytic Leukemia
• Hairy Cell Leukemia
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms
• Lymphoid Malignancies
• Plasma Cell Disorders
• Hematologic Malignancy Pharmacotherapy
• Targeted Therapies
• Cellular and Immune-Based Therapies

The official 2026 agenda specifically includes CML, MPN, MDS, ALL, CLL, hairy cell leukemia, AML, immune-based therapies, and targeted therapies in hematologic malignancies.

Stem Cell Transplantation and Cellular Therapy

• Hematopoietic Stem Cell Transplantation
• Transplant Supportive Care
• Cellular Therapy
• Immune-Based Cancer Therapy
• Treatment Toxicities
• Post-Transplant Complications
• Infection Prevention and Management

The 2026 program includes dedicated education on stem cell transplant supportive care and management of cellular and immune-based therapies in cancer.

Classical and Non-Malignant Hematology

• Anemia
• Hemoglobin Disorders
• Red Cell Disorders
• Platelet Disorders
• Coagulation Disorders
• Thrombosis
• Bleeding Disorders
• Transfusion Medicine
• Bone Marrow Failure
• Benign Hematologic Disorders

Cancer Pharmacology and Targeted Therapy

• Clinical Pharmacology in Oncology
• Targeted Cancer Therapies
• Molecularly Guided Treatment
• Precision Oncology
• Immunotherapy
• Cellular Therapy
• Pharmacologic Management of Hematologic Malignancies
• Treatment Toxicity
• Supportive Pharmacotherapy

Molecular Oncology and Cancer Genetics

• Molecular Genetics of Cancer
• Genomic Alterations
• Molecular Risk Assessment
• Cancer Predisposition
• Hereditary Cancer Syndromes
• Biomarkers
• Molecular Diagnostics
• Precision Medicine
• Targeted Therapeutics

Supportive Oncology

• Supportive Care in Cancer
• Treatment-Related Complications
• Infectious Complications
• Symptom Management
• Palliative Care
• Cancer Pain Management
• Hematologic Support
• Transfusion Support
• Toxicity Management

The official schedule includes a dedicated session on infectious complications in patients with hematologic malignancies.

Board Review Focus

A major purpose of the course is preparation for the ABIM Hematology and Medical Oncology subspecialty examinations.

The curriculum helps learners review:

• High-yield hematology concepts
• High-yield medical oncology concepts
• Current standards of care
• Diagnostic algorithms
• Cancer staging
• Treatment selection
• Molecular testing
• Clinical pharmacology
• Targeted therapy
• Immunotherapy
• Hematologic malignancies
• Classical hematology
• Solid tumor management

MD Anderson specifically states that the program is designed to support certification and recertification preparation in Hematology and Medical Oncology.

Planning Committee / Course Directors

UT MD Anderson Cancer Center

• Sharon Giordano, MD, MPH — Co-Director
• Tapan Kadia, MD — Co-Director
• Shreyaskumar Patel, MD
• Alessandra Ferrajoli, MD
• Nishin Bhadka, MD
• Felisha Estelle

Baylor College of Medicine

• Martha Mims, MD, PhD — Co-Director

These individuals are listed by MD Anderson as members of the 2026 planning committee.

Selected 2026 Faculty and Sessions

The official 2026 schedule includes faculty such as:

• Scott Kopetz, MD — Colorectal Cancer
• Jorge Cortes, MD — Chronic Myeloid Leukemia
• Raajit Rampal, MD, PhD — Myeloproliferative Neoplasms
• Tapan M. Kadia, MD — Myelodysplastic Syndrome
• Hagop M. Kantarjian, MD — Acute Lymphoblastic Leukemia
• Betty Hamilton, MD — Stem Cell Transplant Supportive Care
• Susan O’Brien, MD — Chronic Lymphocytic Leukemia and Hairy Cell Leukemia
• Courtney D. DiNardo, MD — Acute Myeloid Leukemia
• Paolo Strati, MD — Cellular and Immune-Based Therapies
• Samuel A. Shelburne III, MD — Infectious Complications in Hematologic Malignancies
• Caitlin R. Rausch, PharmD, BCOP — Targeted Therapies in Hematologic Malignancies

These faculty-session pairings are taken directly from the published 2026 MD Anderson agenda.

Target Audience

Specialties

• Colon and Rectal Surgery
• Gynecologic Oncology
• Hematology
• Medical Oncology
• Neurological Surgery
• Obstetrics and Gynecology
• Thoracic Surgery
• Urology

Professions

• Nurse – APRN
• Nurse – LVN
• Nurse – RN
• Pharmacist
• Pharmacy Technician
• Physician (MD or DO)
• Student or Trainee

These specialties and professional groups are listed in the official MD Anderson 2026 program.

Best For

This program is particularly relevant for:

• Medical Oncologists
• Hematologists
• Hematology-Oncology Fellows
• Thoracic Surgeons
• Otolaryngologists / Head and Neck Surgeons
• Endocrinologists
• Neuro-Oncologists
• Neurological Surgeons
• Gynecologic Oncologists
• Palliative Care Physicians
• Medical Geneticists
• Breast Surgical Oncologists
• Urologists
• Dermatologists
• Gastroenterologists
• Infectious Disease Specialists
• Transfusion Medicine Specialists
• Hematopathologists
• Oncology Pharmacists
• Advanced Practice Providers
• Residents and Fellows preparing for board examinations

Why This Course Is Relevant

Hematology and medical oncology continue to evolve rapidly as molecular diagnostics, immunotherapy, targeted treatments, cellular therapies, precision oncology, and risk-directed treatment strategies become increasingly integrated into everyday clinical practice.

The MD Anderson Comprehensive Board Review in Hematology and Medical Oncology 2026 provides a concentrated review of both fundamental board-tested concepts and contemporary standards of cancer care.

For fellows and physicians preparing for ABIM Hematology or Medical Oncology certification and recertification, the program offers structured coverage across malignant hematology, classical hematology, solid tumors, pharmacology, molecular oncology, transplantation, immunotherapy, and supportive care.

It is also highly relevant for practicing clinicians seeking a broad update from MD Anderson and Baylor faculty on modern hematology and oncology management.

Short Description

The University of Texas MD Anderson Cancer Center A Comprehensive Board Review in Hematology and Medical Oncology 2026 is a six-day comprehensive ABIM board review covering solid tumors, malignant and classical hematology, leukemia, lymphoma, stem cell transplantation, targeted therapy, immunotherapy, molecular oncology, supportive care, and current standards in cancer treatment.

 

Topics

• Monday, September 14, 2026

  • Welcome and Introduction

  • Early Stage and Locally Advanced Non-Small Cell Lung Cancer

  • Metastatic Non-Small Cell Lung Cancer

  • Small Cell Lung Cancer

  • Head and Neck Cancer

  • Thyroid Cancer

  • Q & A Panel Discussion (Lung Cancer, Head and Neck Cancer, Thyroid Cancer)

  • ASH ASCO Choosing Wisely Recommendations

  • Neuro-Oncology

  • Cervical Cancer and Endometrial Cancer

  • Ovarian Cancer and Unusual Ovarian Histologies

  • Palliative Care

  • Q & A Panel Discussion (Neuro-Oncology, Gynecologic Oncology, Palliative Care)

  • Solid Tumor Q & A Session 1: Lung Cancer, Head and Neck Cancer, Thyroid Cancer, Neuro-Oncology, Gynecologic Oncology

• Tuesday, September 15, 2026

  • Pharmacology I: Chemotherapy

  • Pharmacology II: Targeted Therapy (Alk, EGFR, VEGR, HER2, HH, mTOR)

  • Genetic Risk Factors

  • Sarcoma

  • Q & A Panel Discussion (Pharmacology, Genetic Risk Factors, Sarcoma)

  • Screening/Local Management of Breast Cancer

  • Systemic Treatment of Primary Breast Cancer

  • Metastatic Breast Cancer

  • Special Issues in Breast Cancer

  • Q & A Panel Discussion (Breast Cancer)

  • Solid Tumor Q & A – Session 2: Pharmacology / Genetic Risk Factors / Sarcoma / Breast Cancer

• Wednesday, September 16, 2026

  • Testicular Cancer

  • Urothelial Cancer

  • Renal Cell Carcinoma

  • Prostate Cancer

  • Melanoma

  • Q & A Panel Discussion (Genitourinary Oncology, Melanoma)

  • Pancreaticobiliary Cancers / Unknown Primary

  • Gastroesophageal Cancers / Hepatocellular Carcinoma

  • Colorectal Cancer: Biology and Adjuvant Therapy

  • Metastatic Colorectal Cancer and Anal Cancer

  • Q & A Panel Discussion (Gastrointestinal Oncology)

  • Solid Tumor Q & A – Session 3: Genitourinary Oncology / Gastrointestinal Oncology / Melanoma

• Thursday, September 17, 2026

  • Chronic Myeloid Leukemia

  • Myeloproliferative Neoplasms

  • Myelodysplastic Syndrome

  • Acute Lymphoblastic Leukemia

  • Stem Cell Transplant Supportive Care

  • Q & A Panel Discussion (MPN, MDS, Leukemia, SCT)

  • Chronic Lymphocytic Leukemia and Hairy Cell Leukemia

  • Acute Myeloid Leukemia

  • Management of Cellular and Immune Based Therapies in Cancer

  • Infectious Complications in Patients with Hematologic Malignancies

  • Targeted Therapies in Hematologic Malignancies

  • Q & A Panel Discussion (Leukemia, Therapies, Infectious Complications)

  • Malignant Hematology Q & A Session

• Friday, September 18, 2026

  • Classification of Lymphoma

  • Aggressive Non-Hodgkin Lymphoma

  • Indolent Non-Hodgkin Lymphoma

  • Hodgkin Lymphoma

  • Multiple Myeloma and Other Plasma Cell Dyscrasias

  • Q & A Panel Discussion (Lymphoma, Myeloma)

  • Sickle Cell Anemias, Thalassemia, and Hemoglobinopathies

  • Approach to Anemia

  • Issues in Transfusion Medicine

  • Disorders of Platelet Function

  • Thrombocytopenias

  • Q & A Panel Discussion (Red Cell Disorders, Transfusion Medicine, Platelets)

• Saturday, September 19, 2026

  • Benign Hematology Q & A Session

  • Antithrombotic & Antiplatelet Therapy

  • Normal Coagulation

  • Coagulation Factor Deficiencies, Including von Willebrand Disease and Hemophilias

  • Hypercoagulable States

  • Q & A Panel Discussion (Coagulation, Antithrombotic Therapy)

  • Iron Deficiency and Hemochromatosis

  • Hematopoietic Growth Factors

  • Bone Marrow Failure

  • Leukopenia and Leukocytosis

  • Hemolytic Anemias

  • Q & A Panel Discussion (General Hematology Topics, Red Cell Disorders)